EKF Diagnostics Investor Announcements
EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.
The open offer to qualifying participants has been over-subscribed.
EKF Diagnostics announces that it has entered into a conditional agreement to acquire Selah Genomics, Inc. and DiaSpect Medical AB.a Swedish based manufacturer of point-of-care haemoglobin analysers.
EKF Diagnostics announces its audited final results for the year ended 31 December 2013, a year of strong organic growth and improved earnings.
EKF Diagnostics Holdings plc announces its unaudited interim results for the six months ended 30 June 2013.
Final results for the year ended 31 December 2012.
EKF Diagnostics announces that it has established a new subsidiary, EKF Molecular Diagnostics Limited (“EKF Molecular”), to focus on molecular and companion diagnostics.
EKF announces 2012 Interim Results.
EKF Diagnostics announces that subsidiaries of EKF have entered into a Settlement Agreement with HemoCue AB and HemoCue Inc in relation to patent-related litigation in Germany and the US.
EKF Diagnostics announces that it has signed an exclusive license agreement with the Joslin Diabetes Center (“Joslin”).
EKF Diagnostics announces that it has sold its Swiss subsidiary, International Brand Licensing AG for a cash consideration of £50,000, payable over a two year period.